Li Wang
Subscribe to Li Wang's PostsLi Wang focuses her practice on transactional matters including mergers and acquisitions and private equity transactions in the healthcare industry as well as healthcare regulatory and compliance matters, including fraud and abuse, corporate practice of medicine and Medicare and Medicaid enrollment. Li also has significant experience advising on regulatory matters related to HIPAA, health information privacy and security, genetic privacy, data subject consent requirements and research compliance. Read Li Wang's full bio.
Major Changes Proposed to Substance Use Disorder Confidentiality Law
By Scott Weinstein, Edward G. Zacharias, Abby Higgins and Li Wang on Jan 24, 2023
Posted In Employee Benefits, Health and Welfare Plans
In a Notice of Proposed Rulemaking published December 2, 2022 (the Proposed Rule), the United States Department of Health and Human Services (HHS) proposed long-awaited changes to the regulations protecting the confidentiality of substance use disorder patient records under Part 2 of Title 42 of the Code of Federal Regulations (42 CFR Part 2, or...
Continue Reading
